C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 116 filers reported holding C4 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $104,887 | -31.8% | 56,391 | +0.9% | 0.00% | – |
| Q2 2023 | $153,753 | -29.5% | 55,910 | -19.5% | 0.00% | – |
| Q1 2023 | $218,101 | +127.8% | 69,459 | +328.1% | 0.00% | – |
| Q4 2022 | $95,733 | -32.6% | 16,226 | -0.2% | 0.00% | – |
| Q3 2022 | $142,000 | +35.2% | 16,256 | +17.3% | 0.00% | – |
| Q2 2022 | $105,000 | -96.9% | 13,855 | -90.0% | 0.00% | -100.0% |
| Q1 2022 | $3,358,000 | -77.5% | 138,412 | -70.2% | 0.00% | -75.0% |
| Q4 2021 | $14,948,000 | -28.9% | 464,202 | -1.3% | 0.00% | -20.0% |
| Q3 2021 | $21,023,000 | +18.4% | 470,523 | +0.2% | 0.01% | +25.0% |
| Q2 2021 | $17,761,000 | -21.2% | 469,395 | -23.0% | 0.00% | -33.3% |
| Q1 2021 | $22,553,000 | +126.5% | 609,719 | +102.9% | 0.01% | +100.0% |
| Q4 2020 | $9,957,000 | – | 300,542 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |